Clik here to view.
Cantargia and BioWa Extend Ongoing Collaboration around the POTELLIGENT®...
LUND, Sweden & PRINCETON, N.J. Cantargia AB and BioWa Inc. have signed an extension of the license agreement around the BioWa proprietary POTELLIGENT® Technology for production of Cantargia’s...
View ArticleClik here to view.
Pancreatic Cancer Action Network and CDISC Partner to Develop First...
MANHATTAN BEACH, Calif & AUSTIN, Texas The Pancreatic Cancer Action Network (PanCAN), the leading pancreatic cancer patient advocacy organization, and CDISC, the global nonprofit dedicated to...
View ArticleClik here to view.
玫琳凯基金会携手德克萨斯大学西南医学中心，致力于在全球范围内消除影响女性健康的癌症
达拉斯 (美国商业资讯)–专注于消除癌症对女性影响方面长达数十年的领导者玫琳凯基金会(The Mary Kay FoundationSM)近日宣布拨款50万美元，用于资助与其长期合作伙伴德克萨斯大学西南医学中心(UT Southwestern Medical...
View ArticleClik here to view.
Clik here to view.
ITM and DCB Sign Exclusive Licensing & Development Agreement for Solucin® TRT...
MUNICH & GARCHING, Germany ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical group of companies, and DuChemBio Co, Ltd. (DCB), a leading Korean...
View ArticleClik here to view.
Astex Pharmaceuticals Announces That Its Novel, Oral Hypomethylating Agent...
PLEASANTON, Calif. Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, announces that the US Food & Drug Administration (FDA) has...
View ArticleClik here to view.
Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage...
INGELHEIM, Germany & MUMBAI, India Boehringer Ingelheim and Lupin Limited (Lupin) today announced a licensing, development and commercialization agreement for Lupin’s MEK inhibitor compound...
View ArticleClik here to view.
インサイトがオンコロジーポートフォリオのデータを2019年ESMO大会で発表
米デラウェア州ウィルミントン （ビジネスワイヤ） — インサイト（Nasdaq:INCY）は、当社オンコロジーポートフォリオのデータを中心とするアブストラクトを、2019年9月27日～10月1日にスペインのバルセロナで開催される2019年欧州臨床腫瘍学会（ESMO）大会で報告することを発表します。...
View ArticleClik here to view.
Mevion’s CBCT Imaging Solution from medPhoton Receives FDA Clearance
LITTLETON, Mass. Mevion Medical Systems is pleased to announce its strategic partner, medPhoton GmbH, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the...
View ArticleClik here to view.
IMS Reports the Multidisciplinary Approaches to Minimally Invasive Cancer...
TOKYO Ryusuke Fujiki, Clinical Head and President of Fujiki Hospital, lectured about multidisciplinary approaches which are getting remarkable effect to minimally invasive cancer treatment using JCI...
View ArticleClik here to view.
CANbridge Pharmaceuticals’ Hunterase® Granted Priority Review by the Chinese...
BEIJING & SHANGHAI CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, announced...
View ArticleClik here to view.
三叶草生物制药在研1类新药SCB-313中国腹膜肿瘤I期临床完成首例患者给药
北京 (美国商业资讯)– 三叶草生物制药，一家致力于创新及变革性生物药物研发的生物制药公司，今天宣布在中国进行的SCB-313 I期临床试验完成首例患者给药，该项研究针对出现腹膜肿瘤的癌症患者。SCB-313是一种创新重组人肿瘤坏死因子相关凋亡诱导配体（TRAIL）- 三聚体融合蛋白。...
View ArticleClik here to view.
Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in...
BEIJING Clover Biopharmaceuticals, a biotechnology company focused on developing novel and transformative biologic therapies, today announced that the first patient was dosed in a Phase I trial of...
View ArticleClik here to view.
Atomwise Announces Largest China-US Collaboration for AI Drug Discovery
SAN FRANCISCO Atomwise Inc. (“Atomwise”), the leader in artificial intelligence (AI) for drug discovery, today announced a collaboration with Hansoh Pharmaceutical Group Company Limited (“Hansoh...
View ArticleClik here to view.
Hansoh Pharma and Atomwise Launch Strategic AI Drug Discovery Collaboration...
SHANGHAI & SAN FRANCISCO Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”), a leading biopharmaceutical company in China, and Atomwise, Inc. (“Atomwise”), the leader in artificial...
View ArticleClik here to view.
翰森制药和Atomwise启动多项治疗领域的人工智能药物发现战略合作
上海和旧金山 (美国商业资讯)–中国领先的生物制药公司翰森制药集团有限公司（Hansoh Pharmaceutical Group Company Limited，“翰森制药”）和药物发现人工智能(AI)领域的领先者Atomwise, Inc. (“Atomwise”)宣布合作设计和发现潜在的候选药物，涉及多项治疗领域最多11个未披露的靶蛋白。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
Genome Editing Biotech EdiGene Raises $11 M in Series Pre-B2 Financing and...
BEIJING & CAMBRIDGE, Mass. EdiGene, Inc., which develops genome editing technologies into novel therapeutics for a broad range of diseases and into creative solutions to advance drug discovery,...
View ArticleClik here to view.
Hansoh PharmaとAtomwiseが複数の治療領域を対象としたAI創薬で戦略的協業を開始
上海 & サンフランシスコ （ビジネスワイヤ） — 中国の大手バイオ医薬品企業Hansoh Pharmaceutical Group Company Limited（翰森製薬集団有限公司、ハンソー・ファーマシューティカル）と創薬向け人工知能（AI）分野のリーダー企業Atomwise,...
View ArticleClik here to view.
Solasia Announces Patient Registration Reached Target Number of Cases for...
TOKYO Solasia Pharma K.K. (TSE:4597, Headquarters: Tokyo, President & CEO: Yoshihiro Arai, hereinafter “Solasia”), a specialty pharmaceutical company based in Asia, today announced that patient...
View ArticleClik here to view.
ソレイジア・ファーマ：開発品SP-02 第Ⅱ相臨床試験（最終試験）被験者の目標症例数到達のお知らせ
東京 （ビジネスワイヤ） – 当社は、現在実施中の開発品SP-02（新規抗がん剤、国際一般名：darinaparsin、一般名：ダリナパルシン）の第Ⅱ相臨床試験（以下、「本試験」）について、このたび被験者の登録が目標症例数に到達いたしましたのでお知らせいたします。...
View Article